Health & Fitness
Health and Fitness
Health and Fitness
Mon, July 19, 2010 BIOLASE Appoints Alex Arrow, MD, CFA, and Norman J. Nemoy, MD, FACS, to Board of Directors
IRVINE, CA--(Marketwire - July 19, 2010) - BIOLASE Technology, Inc. (
David M. Mulder, Chairman, CEO and President, commented, "The addition of Alex Arrow and Norman Nemoy brings a wealth of business experience and clinical depth to the Board at a time when we are reshaping the Company and moving forward to return the Company to expansion and profitability. It is rare to find two executives with both an understanding of medicine and how new technologies are developed and adopted, along with the management and industry background necessary to provide guidance to management and stewardship for shareholder rights and value. These two men both have such backgrounds, and we look forward to working with them as we reinvent BIOLASE and move the Company forward."
Alex Arrow, M.D., CFA, has been the Chief Financial Officer of San Carlos, CA-based Arstasis, a commercial stage medical device manufacturer, since 2007. From 2002 to 2007, Dr. Arrow headed medical technology equity research at the global investment bank Lazard, providing research coverage on a wide variety of medical device manufacturers, including BIOLASE, and authoring industry reports spanning the range of medical technology business segments, including the laser industry. Dr. Arrow also spent two years as Chief Financial Officer of the Patent & License Exchange, later renamed PLX Systems, Inc., and three years as the publishing life sciences research analyst at Wedbush Morgan Securities. In 1996, Dr. Arrow was a surgical resident at the UCLA Medical Center. Dr. Arrow received his CFA in 1999. He was awarded an M.D. from Harvard Medical School in 1996 and a B.A. in Biophysics, magna cum laude, from Cornell University in 1992.
Norman J. Nemoy, M.D., F.A.C.S., is a practicing physician at Tower Urology Medical Group and is on the attending staff at both Cedars-Sinai Medical Center and Century City Medical Center. Dr. Nemoy graduated from the University of Illinois School of Medicine, and obtained his urological training at Stanford University Medical Center in Palo Alto, CA. While at Stanford he was honored with an appointment as a U.S. Public Health Fellow. Following his training at Stanford, he had served on the clinical faculty at UCLA School of Medicine. He joined Tower Urology Medical Group in 1986 and is on the surgical attending staff of Cedars-Sinai Medical Center, one of the most prestigious clinical facilities worldwide. He is a fellow of the American College of Surgeons, and is Board Certified by the American Board of Urology.
Dr. Nemoy is an expert in advanced robotic surgery and he has participated in numerous clinical studies designed to test the safety and clinical effectiveness of many new urological and other medical therapies.
About BIOLASE Technology, Inc.
BIOLASE Technology, Inc., the world's leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.
For updates and information on laser and Waterlase dentistry, find BIOLASE at [ http://www.biolase.com ], Twitter at [ http://twitter.com/GoWaterlase ], Facebook at [ http://facebook.com/biolase ], and YouTube at [ http://www.youtube.com/user/Rossca08 ].
This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.
